PDZ domains play a pivotal role in the synaptic localization of ion channels, receptors, signaling enzymes, and cell adhesion molecules. These domains mediate protein-protein interactions via the recognition of a conserved sequence motif at the extreme C terminus of their target proteins. By means of a yeast two-hybrid screen using the C terminus of the G protein-coupled ␣-latrotoxin receptor CL1 as bait, three PDZ domain proteins of the Shank family were identified. These proteins belong to a single protein family characterized by a common domain organization. The PDZ domain is highly conserved among the family members, significantly different from other known PDZ domains, and specifically binds to the C terminus of CL1. Shank1 and CL1 are expressed primarily in brain, and both proteins co-enrich in the postsynaptic density. Furthermore, Shank1 induces a clustering of CL1 in transfected cells, strongly supporting an interaction of both proteins in vivo.
A large class of proteins containing PDZ domains play a general role in the localization of ion channels, signaling molecules, and adhesion molecules to synapses (1) (2) (3) (4) . These functions are exemplified by the defining family of PDZ domain proteins (PSD-95, Dlg, and ZO-1), known as membrane-associated guanylate kinases (MAGUKs). 1 MAGUK proteins include PSD-95/SAP-90 and the closely related PSD-93/chapsyn-110, SAP-97/hdlg, and SAP-102, all of which are found at synapses in brain; the Drosophila PSD-95/SAP-90 homolog, DLG A, which localizes to septate junctions and larval neuromuscular junctions; and ZO-1 and ZO-2, both of which associate with tight junctions between epithelial cells. MAGUKs share a common domain organization, with one or three N-terminal PDZ domains, an SH3 domain, and a C-terminal region homologous to guanylate kinases. PDZ domains mediate protein-protein interactions and typically bind to short amino acid motifs at the C termini of interacting proteins that include certain ion channels, adhesion molecules, and receptors.
A surprising finding was the description of two distinct cell surface receptors for ␣-latrotoxin. This protein is a potent neurotoxin from black widow spider venom (5) . It interacts with Neurexin I␣ in a Ca 2ϩ -dependent manner (6, 7) and with CL1 (CIRL1/latrophilin) in a Ca 2ϩ -independent manner (8) . Interestingly, the C-terminal ends of both receptors contain recognition sequences for PDZ domains (YYV and TSL, respectively). Neurexin I␣ binds to the PDZ domain protein CASK (9) , while the C-terminal binding partner of CL1 is yet unknown. CL1 belongs to the large family of G protein-coupled receptors with seven-transmembrane regions (8) . It is one of the major receptors mediating the release of neurotransmitter from nerve terminals by ␣-latrotoxin action (10) . Based on this finding, a presynaptic localization of CL1 is very likely. Since CL1 antibodies did not function in immunocytochemical studies, the subcellular localization of CL1 remained unclear. However, latrotoxin binding studies in primary cultures of cerebellar neurons revealed that ␣-latrotoxin receptors are localized at pre-and postsynaptic sites (11) .
Interestingly, homologs of CL1, termed CL2 and CL3, were identified (12) . The C-terminal ends of all CL isoforms contain the same PDZ domain recognition sequence (TSL). Thus, it is tempting to speculate that these receptors interact in vivo with a PDZ domain protein. Therefore we performed a yeast twohybrid screen using the last 49 amino acids of CL1 as bait and a rat brain library as source of preys. A detailed analysis of the preys revealed that the yeast two-hybrid method is ideal to identify PDZ domain proteins. 86% of these clones encoded PDZ domain proteins, and 43% of the PDZ clones represented proteins of the Shank family (13, 14) .
Shank proteins define a novel family of scaffold proteins recently identified through their interaction with a variety of cytoplasmic and membrane proteins, such as GKAP or SAPAP (13) (14) (15) (16) , Cortactin (17) , and somatostatin receptor type 2 (18) . At present, the Shank family comprises three members: Shank1, Shank2, and Shank3. The Shank genes were independently cloned by several investigators and are hence known under different names, such as Shank (13) , Synamon (16), ProSAP (19) , CortBP (17) , SSTRIP (18) , and Spank (GenBank accession numbers AF159046, AF159047, and AF159048). Here, we use the name Shank to refer to the family as a whole. This family shares a common domain organization, with ankyrin repeats near the N terminus, an SH3 (Src homology region 3) domain, a PDZ domain, proline-rich regions in the interior, and an SAM (sterile-␣ module) domain at the C terminus. The PDZ domain is highly conserved among the Shank family members, and significantly different from other known PDZ domains. In contrast to the MAGUKs, the PDZ domain of Shank is C-terminal of the SH3 domain, i.e. both domains have switched their relative positions.
In the present study, we demonstrate that the C terminus of CL1 binds specifically to the Shank PDZ domain. We confirm this interaction using three independent methods: first, a genetic approach based on the yeast two-hybrid method; second, a co-sedimentation of Shank1 and GST-CL1 fusion protein; and third, a co-localization of CL1 and Shank1 in double-transfected HEK293 cells. Both proteins are primarily expressed in brain where they co-enrich in the postsynaptic density. Furthermore, in transfected HEK293 cells CL1 is clustered in the presence of full-length Shank1, strongly supporting an interaction of both proteins in vivo.
MATERIALS AND METHODS
Yeast Two-hybrid Screen and Interaction Assay-Yeast strain L40 (20) was sequentially transfected with the bait vector pLexN-CL1 encoding the C terminus of CL1 (amino acids 1423-1471) and a rat brain cDNA library (20) using lithium acetate (21) . Transformants were selected on plates lacking histidine, uracil, tryptophan, lysine, and leucine. Positive clones were picked after 3 days at 30°C, and the ␤-galactosidase activity of the clones was assayed by the filter method. Extrachromosomal DNA was isolated from clones that grew in the absence of histidine and were ␤-galactosidase positive using the glass bead method (22) . Prey plasmids were rescued in Escherichia coli HB101 cells by electroporation and selection on M9 plates containing 50 mg/liter proline and 0.1 g/liter ampicillin. For quantitation of ␤-galactosidase activity, yeast strains transfected with bait and prey vectors were grown in supplemented minimal medium lacking uracil, tryptophan, and leucine in a shaking incubator at 30°C for 48 h. ␤-Galactosidase assays were performed on yeast extracts with protein concentrations of 0.5 mg/ml per assay as described previously (23) . Protein concentrations were determined according to Bradford (24) using bovine serum albumin as a standard.
Cloning of Full-length Shank1-A rat brain library in ZAP II was screened at high stringency (25) with a 0.5-kilobase probe derived from the yeast two-hybrid screen (see above). In vivo excision of the inserts (26) and sequencing in pBluescript revealed that 4 clones overlapped with the clone used as probe. Overlapping clones containing the fulllength coding region of Shank1 were isolated by rescreening phage libraries multiple times. Clones were sequenced by the dideoxynucleotide chain termination method using fluorescently labeled primers and an ABI 370A DNA sequencer. An open reading frame of 6501 nucleotides was found for Shank1. Its start codon is in full agreement with Kozak's rules (CCACGATG (27) ). In addition, a stop codon located 36 nucleotides upstream from the start codon was identified. For Shank2 and -3 only partial clones were obtained. Sequences of Shank1, Shank2, and Shank3 have been submitted to GenBank under the names of Spank1, Spank3, and Spank2 (accession numbers AF159046, AF159048, and AF159047, respectively).
Construction and Expression of Bacterial and Eukaryotic VectorsVectors for the bacterial expression of glutathione S-transferase-Shank fusion proteins were constructed in pGEX-KG (28) . The following pGEX-Shank constructs were engineered: pGEX-Shank1 encoding residues 471-717 (referring to number AF159046); pGEX-Shank2 encoding residues 241-443 (referring to number AF159048); and pGEXShank3 encoding residues 1-469 (referring to number AF159047). For CL1 expression the following pGEX constructs were generated: GSTCL1a encoding amino acids 1422-1471 of rat CL1 and its truncated version GST-CL1b encoding amino acids 1422-1468 (minus TSL construct).
Constructs for expression of His 6 fusion proteins were made as follows: His 6 Shank1 (full-length), His 6 Shank1 encoding residues 480 -662 (PDZ domain), and His 6 CASK. In detail, His 6 Shank1 (full-length) was obtained by the following procedure: first, an EcoRI/BamHI fragment of Shank1 (nucleotides 1092-2065; see cloning of full-length Shank1) was subcloned into pcDNA3 (Invitrogen) predigested with EcoRI and BamHI. This pcDNA3 vector contains an insert encoding an N-terminal His 6 tag. Second, a BamHI fragment of ShankI (nucleotides 10 -1091) was generated by PCR and subcloned into the BamHI site of the construct described in step 1. Third, a Shank1 fragment containing nucleotides 4285-6504 was obtained by PCR using primers with KpnI and XbaI sites. Fourth, an EcoRI/KpnI fragment (nucleotides 2066 -4284) and a KpnI/XbaI fragment (nucleotides 4285-6504) described in step 3 were subcloned into the pBluescript SKII vector (EcoRI/XbaI). Fifth, an EcoRI/XbaI fragment containing nucleotides 2066 -6504 (see step 4) was cloned into the construct described in step 2.
Constructs of His 6 Shank1 encoding residues 480 -662 (PDZ domain) and His 6 CASK (full-length) were obtained by subcloning of the corresponding PCR products into pET-28a (Novagen). Full-length cDNAs of rat CASK and Shank1 (see above) were used as templates for amplification by PCR. Rat CASK cDNA was kindly provided by Dr. T. C. Sü dhof (Howard Hughes Medical Institute, Southwestern Medical Center, Dallas, TX).
A mammalian expression vector encoding full-length CL1 with a green fluorescent protein (GFP) sequence inserted into its cytoplasmic tail was constructed in pCMV5 using an engineered PCR fragment of GFP that ensured reading frame conservation. For this purpose, a KpnI fragment of GFP was subcloned into the KpnI site of full-length CL1. This cloning strategy ensured that the N-terminal signal peptide essential for CL1 targeting and the C terminus essential for interaction with PDZ domain proteins remained unchanged. Full-length CL1 in pCMV5 was obtained from Dr. T. C. Sü dhof.
All PCR-based constructs were verified by dideoxy chain termination sequencing with dye terminators on an Applied Biosystems 373 DNA sequencer (Applied Biosystems). HEK293 and COS cells were transfected with mammalian expression vectors using the calcium phosphate co-precipitation method (29) . Proteins encoded by pGEX-and pETvector constructs were expressed in E. coli and purified as described (28, 30) .
Co-sedimentation Assay-For in vitro binding experiments, immobilized GST-CL1 fusion proteins were mixed with cell extracts from E. coli or HEK293 cells prior to being transformed or transfected with cDNA encoding His 6 Shank1. The cell extracts were obtained by solubilization with a Triton X-100 containing buffer (1% Triton X-100 in phosphatebuffered saline supplemented with protease inhibitors (Roche Molecular Biochemicals)) and subsequent centrifugation for 15 min at 100,000 ϫ g. Cell extracts with a protein concentration of 1 mg/ml were incubated with immobilized GST fusion proteins for 2 h at 4°C. After being washed three times with solubilization buffer, proteins bound to glutathione beads were eluted with SDS sample buffer, separated by SDS-gel electrophoresis, and transferred to nitrocellulose. These proteins were analyzed with a monoclonal antibody specific for the His 6 epitope (Qiagen).
Subcellular Fractionation of Brain Tissue-Subcellular fractionation was performed with minor modifications as described (31) . Brains of 2-month-old rats were homogenized in homogenization buffer (5 mM HEPES, pH 7.4, 320 mM sucrose) containing protease inhibitor mixture (Roche Molecular Biochemicals). Cell debris and nuclei were removed by 1000 ϫ g centrifugation. The supernatant was spun for 20 min at 13,000 ϫ g, resulting in supernatant S2 and pellet P2 (crude membrane fraction). S2 was centrifuged at 100,000 ϫ g for 1 h, and the resulting supernatant was taken as cytoplasmic fraction. The P2 pellet was further fractionated by centrifugation in a sucrose step gradient as described (31) . For isolation of PSD proteins, the synaptosomal fraction of the first gradient was diluted with 320 mM sucrose (60 ml/10 g wet tissue) and an equal volume of 1% Triton X-100, 320 mM sucrose, and 12 mM Tris-HCl, pH 8.1. The suspension was kept on ice for 15 min, and then centrifuged for 30 min at 32,800 ϫ g. The pellet was resuspended in 320 mM sucrose, 1 mM NaHCO 3 (6 ml/10 g wet tissue), and loaded onto a second sucrose gradient. The gradients were spun for 2 h at 201,800 ϫ g. The PSD proteins banded between 1.5 and 2.0 M sucrose. The PSD proteins were further extracted with 0.5% Triton X-100, 75 mM KCl and spun for 20 min at 201,800 ϫ g. The resulting pellet was taken as purified PSD fraction. All steps were performed at 4°C.
Clustering Assay-HEK293 cells were grown on glass coverslips coated with 0.5% gelatin (32) and transfected with a GFP expression vector encoding full-length CL1, a His 6 expression vector encoding full-length Shank1, or a combination of both vectors. A His 6 CASK expression vector was used as a control. Coverslips were mounted onto slides with Fluoromount-G (Southern Biotechnology Associates) and observed with a MRC 1024 confocal laser scanning microscope (Bio-Rad).
Antibodies-Polyclonal rabbit antibodies to Shank1, Shank2, and Shank3 were raised against glutathione S-transferase fusion proteins containing residues 471-717 (Spank1, GenBank accession number AF159046), 241-443 (Spank3, GenBank accession number AF159048), and 1-469 (Spank2, GenBank accession number AF159047). A polyclonal antibody to CL1 was a gift from Dr. T. C. Sü dhof. Monoclonal antibodies to synaptophysin (cl. 7.2) and the NR1 subunit of the Nmethyl-D-asparatate receptor (cl. 54.1) were kindly provided by Dr. R. Jahn (Max Planck-Institute for Biophysical Chemistry, Gšttingen, Germany). A monoclonal antibody specific for the His 6 epitope was purchased from Qiagen.
Miscellaneous Procedures and Materials-SDS-polyacrylamide gel electrophoresis and immunoblotting were performed with minor modifications as described (33, 34) . Immunoreactive bands were visualized with enhanced chemiluminescence (Amersham Pharmacia Biotech). RNA blots were purchased from CLONTECH. The following probes were used: for Shank1, nucleotides 1337-1752 (referring to GenBank entry AF159046); for Shank2, nucleotides 529 -933 (AF159048); and for Shank3, nucleotides 1406 -2039 (AF159047).
RESULTS

Analysis of a Yeast Two-hybrid Screen Using CL1 as
Bait-CL1 is a major ␣-latrotoxin receptor predominantly expressed in brain (8) . Interestingly, its C terminus contains a typical recognition sequence for PDZ domains (TSL). To identify PDZ domain proteins interacting with CL1, we performed a yeast two-hybrid screen using its last 49 C-terminal residues as bait and a prey rat brain library of 85 million yeast clones. 110 were found to be positive in a ␤-galactosidase assay. 45 clones were characterized by sequencing and data base searches. Almost 90% of the sequenced clones encoded proteins with PDZ domains (Table I) , e.g. PSD-95/SAP-90, SAP-102, Magi-1, S-SCAM, and ros1. Combinations of these preys with a bait devoid of the last three amino acids of CL1 did not show any positive ␤-galactosidase activity in a retransformation assay (Table I , column 5, values in brackets). Thus, we conclude that the measured ␤-galactosidase activities depend almost entirely on the existence of the last three amino acids of CL1, implying that PDZ domains mediate the interactions. Only one exception was found. The interaction with KIAA0229 protein was independent of the last three amino acids of CL1, suggesting that PDZ domains are not involved in mediating this interaction. Indeed, a detailed sequence analysis of KIAA0229 did not detect a PDZ domain.
In this screen, almost 40% of all positive clones encoded proteins of the Shank family (13, 14) . Since the yeast twohybrid clones contained only partial coding sequences, we used one of these as probe to screen a rat brain cDNA library. Multiple screens were necessary to obtain the entire reading frame. The full-length clone that we obtained by ligation of four overlapping subclones encoded a protein with 2167 residues. This protein was almost identical with Shank1. Minor differences to the Shank1 sequence (accession number AF131951) were obvious. Shank1 in comparison with our sequence was lacking 72 residues at the N terminus and an internal sequence of 8 residues (residues 797 to 804). Since Shank1 was unknown at that time, we submitted our sequence to GenBank under the name Spank1 (GenBank accession number AF159046).
Domain Structure of the Shank Proteins-The full-length clone of Shank1 that we constructed by ligation of four overlapping clones is composed of six ankyrin repeats near the N terminus, an SH3 domain, a PDZ domain, proline-rich regions in the interior and an SAM domain at the C terminus (Fig. 1A) . Both clones, i.e. Shank2 and -3, show an identical domain composition in the regions available for sequence analysis (Fig.  1A) . Furthermore, a sequence alignment showed unambiguously that they belong to a protein family. Since Shank2 and -3 represent only partial clones, some domains are missing (submitted to GenBank under the names of Spank3 and -2, respectively, GenBank accession numbers AF159048 and AF159047, respectively).
Shank proteins contain one PDZ domain that is highly conserved within the family (Fig. 1B) . Compared with other PDZ domains, e.g. these of PSD-95/SAP-90, SAP-102, and Magi-1, striking differences were observed. In contrast to the MAGUKs, the PDZ domain of Shank is C-terminal of the SH3 domain, i.e. the positions of these domains are switched. The existence of a histidine residue located 23 residues upsteam from the PDZ domain end identifies the PDZ domain of Shank as a member of the PSD-95 group (group 1A according to (35) ).
Tissue-specific Expression of the Shanks-RNA blots loaded with poly(A)-enriched RNA from different rat tissues were hybridized at high stringency with probes specific for the Shank isoforms. mRNAs for all three Shanks were only detected in brain (Fig. 2) . The sizes of the mRNAs for the different isoforms vary from 9.0 (Shank1) to 7.5 (Shank3) and 8.5 kilobases (Shank2). Two other bands detected by cross-hybridization in kidney and lung are different in size compared with the respective Shank mRNAs in brain. However, we cannot rule out the possibility that these bands are due to additional Shank isoforms. Surprisingly, the distribution of Shank3 is different to its reported distribution (36) . According to Lim et al. (36) , Shank3 mRNA is expressed abundantly in heart and moderately in brain and spleen. In our hands, Shank3 mRNA is almost exclusively expressed in brain. At present, the reason for this discrepancy is unknown. It is possible that alternative splice variants of Shank3 are differentially expressed in various tissues. Indeed, such a mechanism is reported for Shank1 and -2 but not for Shank3 (36) .
To study the expression pattern of the Shank proteins, we raised polyclonal antibodies against their bacterially expressed glutathione S-transferase fusion proteins. The Shank1 antibody specifically recognized a high-molecular weight band on immunoblots that were prepared from proteins of Shank1-transfected COS cells (Fig. 3A) . Its molecular mass of 240 kDa is in full agreement with the size of Shank1 comprising 2167 residues. The antibodies raised against recombinant Shank2 and -3 did not detect Shank1 (Fig. 3A) , demonstrating their specificity with regard to Shank1. When immunoblots with proteins of Shank2 and -3 transfected COS cells were used, the Shank2 and -3 antibodies recognized specific bands. The Shank2 antibody did not cross-react with Shank3, and vice versa (data not shown).
We used these antibodies to examine the tissue distribution of the Shank proteins (Fig. 3, B-D) . Shank1 was only detectable in brain tissue (Fig. 3B) , confirming the RNA blotting data (Fig.  2) . The size of the brain protein corresponded to that in transfected COS cells, suggesting that the expression vector encoded full-length Shank1. Shank2 was predominantly expressed in with the C terminus of CL1 as bait To identify proteins interacting with CL1, we used its last 49 Cterminal residues as bait. 85 million yeast clones were co-transfected with the CL1 bait plasmid and plasmids from a rat brain library. Among the analyzed clones, 110 were positive in a ␤-galactosidase assay. Sequencing and subsequent data base searches identified 45 clones. The names of these clones are listed according to their frequency in the screen. The strength of interaction with CL1 was determined with a liquid ␤-galactosidase assay (fifth column, values in arbitrary units). The values in brackets characterize the interaction of the respective clones with the C terminus of CL1 deprived of its last three residues (TSL). 
Name of clone
Interaction of CL1 with Shank Proteins
brain, apparently with a lower expression in lung (Fig. 3C) . However, the lung protein was somewhat smaller than its counterpart in brain. Surprisingly, the corresponding isoform was not detectable on RNA blots (Fig. 2) , implying that the lung protein is not related to Shank2. In agreement with its mRNA distribution (Fig. 2) , the Shank3 protein was mainly found in brain and in lower amounts in lung (Fig. 3D) . Taken together, the predominant expression of all known Shanks in brain is similar on the RNA and protein level, suggesting a functional role of all Shank isoforms in this tissue.
Shank1 and CL1 Co-enrich in the Postsynaptic
DensitySince the antibodies against Shank1 and CL1 did not give a specific staining in immunocytochemistry, we performed subcellular fractionations as a first step to localizing both proteins (Fig. 4) . As described by Carlin et al. (31) , synaptosomes were isolated from brain homogenates and extracted twice with Triton X-100 to obtain a highly purified postsynaptic density fraction (PSD). To characterize the subcellular fractions, control antibodies for proteins with a well characterized localization were used. Synaptophysin is a presynaptic marker protein (P2,
FIG. 1. Domain structure of the Shanks and sequence alignment of their PDZ domains. A, diagram of the domain structures of Shank1
and its homologs. The domain structure of Shank1 represents its entire coding region, whereas Shank2 and -3 represent partial clones that we found in a yeast two-hybrid screen. PDZ denotes a conserved domain named for the first known representatives PSD95, Dlg, and ZO-1. The Shank family members have a unique structure of domains arranged as follows: six ankyrin repeats near the N terminus, one SH3 domain, one PDZ domain and one SAM domain at the C terminus. Since the Shank family was discovered by several investigators independently, different names emerged. These names are listed on the right side of the respective Shank isoforms. B, sequence alignment of selected PDZ domains. Sequences are aligned for maximal homology. The PDZ domain of the Shanks is highly conserved within the Shank family but significantly different from other PDZ domains.
FIG. 2. Expression of Shank1
, -2, and -3 in rat tissues analyzed by RNA blotting. Blots containing poly(A)-enriched RNA from the indicated rat tissues were hybridized at high stringency with radioactively labeled probes from the coding regions of Shank1, -2, and -3 and exposed to film for 24 h. The same blots were rehybridized with an actin probe as loading control, demonstrating that equal amounts of RNA were loaded onto the gels (data not shown). The blots show that Shank1, -2, and -3 are exclusively expressed in brain. Additional isoforms with different sizes may exist in other tissues (e.g. lung and kidney).
P3, and synaptosomes) located on synaptic vesicles and not found in the cytosol (S2) and PSD. Conversely, the NR1 subunit of the N-methyl-D-asparatate receptor is a postsynaptic density marker (PSD fractions, once and twice extracted with Triton). Shank1 and CL1 were highly enriched in the postsynaptic density fraction, demonstrating a localization of both proteins in the same subcellular compartment.
Shank1 Binds to Recombinant CL1-CL1 is a highly brainenriched protein with seven-transmembrane regions (8) . In vivo, CL1 is processed into two fragments with distinct biochemical properties (8) . The larger, N-terminal fragment (120 kDa) binds to ␣-latrotoxin and is located extracellularly. It is highly glycosylated and soluble under normal physiological conditions. In contrast, the C-terminal fragment of CL1 (85 kDa) contains seven-transmembrane regions and the C-terminal recognition site for PDZ domain proteins. It is insoluble in physiological buffers, even in the presence of Triton X-100 or SDS. Only in the presence of high urea and SDS concentrations the C-terminal subunit of CL1 could be solubilized (8) . Since these experimental conditions abolish any physiological interaction, we could not show a co-immunoprecipitation of CL1 and Shank1 in brain homogenates.
Instead, we studied whether Shank1 could interact with a soluble version of CL1 comprising its last 50 C-terminal residues. As a control, a truncated version of CL1 devoid of its last three C-terminal residues was used. Both Shank1 constructs, a full-length version of Shank1 and a truncated version containing its PDZ domain, interacted specifically with CL1 (Fig. 5) . Shank1 did not bind to the truncated version of CL1 lacking its last three C-terminal amino acids (Fig. 5) . These results demonstrate a specific interaction of CL1 and Shank1 under in vitro conditions. Shank1 and CL1 Co-cluster in Double-transfected HEK293 Cells-To study an interaction of Shank1 and CL1 in vivo, we looked for co-localization of these proteins in transfected HEK293 cells (Fig. 6) . Full-length CL1 containing a GFP sequence inserted into its intracellular tail was almost exclusively located at or near the plasma membrane, indicating that the targeting of CL1 in transfected HEK293 cells was correct (Fig. 6A) . In cells co-expressing CL1 and Shank1, CL1 redis- tributed into plaque-like clusters in which both proteins were highly co-localized (Fig. 6F, in yellow) . However, in cells coexpressing CL1 and the PDZ domain protein CASK, CL1 did not redistribute (Fig. 6, G and I) . This result is not surprising, since CL1 and CASK do not interact (data not shown). According to a classification of PDZ domains (35) , CASK belongs to type 2 and requires a binding partner with a recognition site that is different from that of CL1. Note that the expression of full-length Shank1 already gave rise to cluster-like structures, changing the cell morphology from a spindle-like to a round shape (Fig. 6, A and B) . This clustering is consistent with the biochemical properties of full-length Shank1 that include the ability to self-multimerize via its SAM domain (13) . In summary, the co-clustering of CL1 and Shank1 provides strong evidence for an interaction of both proteins in vivo. DISCUSSION PDZ domains are one of the most exciting domains mediating protein-protein interactions. Compelling evidence derived from genetic analysis in Caenorhabditis elegans and Drosophila, in combination with studies in transfected eukaryotic cells, demonstrates that PDZ domains function in clustering receptors, channels, and adhesion molecules (37) (38) (39) . By clustering these molecules, their concentration at specific subcellular sites is dramatically increased and a connection to downstream signaling pathways is achieved (1-4).
Our study was aimed at finding specific binding partners for the calcium-independent ␣-latrotoxin receptor CL1 (8) . Three reasons led us to use CL1 as bait in a yeast two-hybrid screen. First, specific interacting partners for CL1 are still unknown. Second, the C terminus of CL1 contains a typical recognition sequence for PDZ domains. Third, CL1 is a member of the large family of G protein-coupled receptors and most likely involved in signaling pathways.
More than 10 different PDZ domain proteins emerged from our screen. The question now arises as to which protein is the in vivo interacting partner of CL1. The Shanks (13, 14) represented almost 40% of the positive yeast two-hybrid prey clones, implying that the Shanks may interact intracellularly with the C terminus of CL1. RNA blots revealed that all three Shank isoforms are primarily expressed in brain, fitting well to the . G-I, these 293 cells were doubletransfected with full-length GFP-CL1 and full-length His 6 -CASK (in red). CL1 was predominantly expressed at the plasma membrane and showed an equal distribution (A). In the presence of Shank1, CL1 changed its distribution and formed clusters in the vicinity of the plasma membrane (D). The CL1 clusters strongly overlapped with those of Shank1 (in yellow, F), demonstrating a co-clustering of CL1 and Shank1. However, in the presence of the PDZ domain protein CASK, the intracellular localization of CL1 remained unchanged (G and I). Please note that the expression of full-length Shank1 induced a change in the cell shape (compare B and C), most likely due to the fact that fulllength Shank1 alone formed huge clusters (B). expression pattern of CL1 (12) . Using specific antibodies raised against recombinant Shank proteins, we were able to show that all three Shank proteins are highly enriched in brain. In addition, Shank1 and CL1 co-localized in a postsynaptic density fraction, indicating that both proteins reside in the same subcellular compartment. We confirmed the yeast two-hybrid results by two additional, independent interaction assays: in vitro Shank1 binds to recombinant CL1, and in vivo CL1 coclusters with Shank1 in double-transfected HEK293 cells. Thus, three independent interaction assays in combination with localization studies provide strong evidence for a physiologically relevant interaction of Shank proteins with CL1.
Surprisingly, the ␣-latrotoxin receptor CL1 is localized at pre-and postsynaptic sites (11) . However, its binding partner Shank1 is almost exclusively expressed at postsynaptic sites (13) . This localization pattern raises two intriguing questions. First, is the interaction of both proteins confined to the postsynaptic site? Second, which is the presynaptic binding partner of CL1? At present, we cannot answer these questions. It seems that the Shank1-CL1 interaction is confined to the postsynapse due to the Shank1 localization at the postsynaptic density of asymmetric synapses (13) . However, the subcellular localization of Shank2 and -3 is not known. In developing neurons in culture, Shank2 (CortBP1) immunoreactivity is concentrated in growth cones of axons and dendrites (17) . This finding raises the possibility that CL1 interacts with Shank2 at pre-and postsynaptic sites. Further immunoelectron microscopy studies for the Shank and CL proteins are necessary to clarify the subcellular localization of these protein families.
Which is the functional significance of the CL1-Shank interaction? As shown in Fig. 6 , Shank clusters CL1 in the vicinity of the plasma membrane. Thus, Shank increases the concentration of CL1 at a defined subcellular location. CL1 is a G protein-coupled receptor, most likely involved in the transduction of extracellular signals into pre-or postsynaptic sites (10) . It is tempting to speculate that Shank proteins increase the CL1 concentration at specific subcellular sites and thereby enable a connection of CL1 to downstream signaling pathways.
Shank (ProSAP) proteins are believed to function in the early development of the nervous system, based on the time course of Shank expression and its interaction with the actin-binding protein cortactin (19) . The existence of an SAM domain identified in Shank proteins further underlines their potential roles in developmental regulation and/or synaptogenesis. For several SAMcontaining proteins, developmental regulation has been directly shown by experiments. For instance, SAM domains in receptor tyrosine kinases of the Eph subfamily are implicated in the regulation of brain patterning (40) . Interestingly, the crystal structure of the SAM domain from the Eph receptor tyrosine kinase EphB2 supports the notion that SAM domains can cluster membrane proteins due to the existence of two different interfaces (41) . At present, similar data for the Shank proteins are not available. However, Shank proteins self-multimerize via their SAM domain (13) . Further experiments will be needed to elucidate the functional significance of the various Shank domains for interaction with CL1 and other binding partners.
